476 related articles for article (PubMed ID: 18578523)
1. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
Sardana G; Jung K; Stephan C; Diamandis EP
J Proteome Res; 2008 Aug; 7(8):3329-38. PubMed ID: 18578523
[TBL] [Abstract][Full Text] [Related]
2. Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer.
Gross M; Top I; Laux I; Katz J; Curran J; Tindell C; Agus D
Clin Cancer Res; 2007 Apr; 13(7):1979-86. PubMed ID: 17404077
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer.
Gunawardana CG; Kuk C; Smith CR; Batruch I; Soosaipillai A; Diamandis EP
J Proteome Res; 2009 Oct; 8(10):4705-13. PubMed ID: 19663500
[TBL] [Abstract][Full Text] [Related]
4. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry.
Garbis SD; Tyritzis SI; Roumeliotis T; Zerefos P; Giannopoulou EG; Vlahou A; Kossida S; Diaz J; Vourekas S; Tamvakopoulos C; Pavlakis K; Sanoudou D; Constantinides CA
J Proteome Res; 2008 Aug; 7(8):3146-58. PubMed ID: 18553995
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.
Pang B; Zhang H; Wang J; Chen WZ; Li SH; Shi QG; Liang RX; Xie BX; Wu RQ; Qian XL; Yu L; Li QM; Huang CF; Zhou JG
Prostate; 2009 Aug; 69(11):1176-87. PubMed ID: 19415690
[TBL] [Abstract][Full Text] [Related]
6. Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis.
Bouchal P; Roumeliotis T; Hrstka R; Nenutil R; Vojtesek B; Garbis SD
J Proteome Res; 2009 Jan; 8(1):362-73. PubMed ID: 19053527
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers for prostate cancer detection.
Parekh DJ; Ankerst DP; Troyer D; Srivastava S; Thompson IM
J Urol; 2007 Dec; 178(6):2252-9. PubMed ID: 17936845
[TBL] [Abstract][Full Text] [Related]
8. Novel breast cancer biomarkers identified by integrative proteomic and gene expression mapping.
Ou K; Yu K; Kesuma D; Hooi M; Huang N; Chen W; Lee SY; Goh XP; Tan LK; Liu J; Soon SY; Bin Abdul Rashid S; Putti TC; Jikuya H; Ichikawa T; Nishimura O; Salto-Tellez M; Tan P
J Proteome Res; 2008 Apr; 7(4):1518-28. PubMed ID: 18318472
[TBL] [Abstract][Full Text] [Related]
9. Proteomics for the identification of new prostate cancer biomarkers.
Ornstein DK; Tyson DR
Urol Oncol; 2006; 24(3):231-6. PubMed ID: 16678055
[TBL] [Abstract][Full Text] [Related]
10. Development of selected reaction monitoring-MS methodology to measure peptide biomarkers in prostate cancer.
Yocum AK; Khan AP; Zhao R; Chinnaiyan AM
Proteomics; 2010 Oct; 10(19):3506-14. PubMed ID: 20821805
[TBL] [Abstract][Full Text] [Related]
11. Molecular markers of prostate cancer.
Bradford TJ; Tomlins SA; Wang X; Chinnaiyan AM
Urol Oncol; 2006; 24(6):538-51. PubMed ID: 17138135
[TBL] [Abstract][Full Text] [Related]
12. [Markers for diagnosis, prediction and prognosis of prostate cancer].
Taskén KA; Angelsen A; Svindland A; Eide T; Berge V; Wahlquist R; Karlsen S
Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3279-82. PubMed ID: 16327854
[TBL] [Abstract][Full Text] [Related]
13. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis.
Pang J; Liu WP; Liu XP; Li LY; Fang YQ; Sun QP; Liu SJ; Li MT; Su ZL; Gao X
J Proteome Res; 2010 Jan; 9(1):216-26. PubMed ID: 19894759
[TBL] [Abstract][Full Text] [Related]
14. Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer.
Whiteaker JR; Zhang H; Zhao L; Wang P; Kelly-Spratt KS; Ivey RG; Piening BD; Feng LC; Kasarda E; Gurley KE; Eng JK; Chodosh LA; Kemp CJ; McIntosh MW; Paulovich AG
J Proteome Res; 2007 Oct; 6(10):3962-75. PubMed ID: 17711321
[TBL] [Abstract][Full Text] [Related]
15. Efficient isolation and quantitative proteomic analysis of cancer cell plasma membrane proteins for identification of metastasis-associated cell surface markers.
Lund R; Leth-Larsen R; Jensen ON; Ditzel HJ
J Proteome Res; 2009 Jun; 8(6):3078-90. PubMed ID: 19341246
[TBL] [Abstract][Full Text] [Related]
16. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
17. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models.
Denmeade SR; Sokoll LJ; Chan DW; Khan SR; Isaacs JT
Prostate; 2001 Jun; 48(1):1-6. PubMed ID: 11391681
[TBL] [Abstract][Full Text] [Related]
18. [Serum osteoprotegerin as a novel marker of bone metastasis in prostate cancer].
Chen HX; Li HZ; Li HJ; Shi BB; Jin W; Cheng XQ
Zhonghua Wai Ke Za Zhi; 2007 Mar; 45(6):412-4. PubMed ID: 17537330
[TBL] [Abstract][Full Text] [Related]
19. Prostate specific antigen in the diagnosis and staging of prostate cancer.
Jung P; Wolff JM; Mattelaer P; Jakse G
Acta Urol Belg; 1996 Sep; 64(3):1-6. PubMed ID: 8946774
[TBL] [Abstract][Full Text] [Related]
20. Serum markers for prostate cancer: a rational approach to the literature.
Steuber T; O'Brien MF; Lilja H
Eur Urol; 2008 Jul; 54(1):31-40. PubMed ID: 18243505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
